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RESEARCH ARTICLE
Brucella melitensis Rev.1 vaccination 
generates a higher shedding risk of the vaccine 
strain in Alpine ibex (Capra ibex) compared 
to the domestic goat (Capra hircus)
Claire Ponsart1†, Mickaël Riou2*†, Yann Locatelli3†, Isabelle Jacques4,5†, Alain Fadeau6, Maryne Jay1, 
Roland Simon3, Ludivine Perrot1, Luca Freddi1, Sylvain Breton2, Thierry Chaumeil2, Barbara Blanc3, Katia Ortiz3, 
Colin Vion3, Damien Rioult7, Erwan Quéméré8, Pierre Sarradin2, Jean‑Yves Chollet9, Bruno Garin‑Bastuji10 
and Sophie Rossi9†
Abstract 
Epidemiological investigations implemented in wild and domestic ruminants evidenced a reservoir for Brucella in 
Capra ibex in the French Alps. Vaccination was considered as a possible way to control Brucella infection in this wildlife 
population. Twelve ibexes and twelve goats were allocated into four groups housed separately, each including six 
males or six non‑pregnant females. Four to five animals were vaccinated and one or two animals were contact ani‑
mals. Half of the animals were necropsied 45 days post‑vaccination (pv), and the remaining ones at 90 days pv. Addi‑
tional samples were collected 20 and 68 days pv to explore bacterial distribution in organs and humoral immunity. 
Neither clinical signs nor Brucella‑specific lesions were observed and all vaccinated animals seroconverted. Brucella 
distribution and antibody profiles were highly contrasted between both species. Proportion of infected samples was 
significantly higher in ibex compared to goats and decreased between 45 and 90 days pv. Two male ibex presented 
urogenital excretion at 20 or 45 days pv. The bacterial load was higher 45 days in ibexes compared to goats, whereas 
it remained moderate to low 90 days pv in both species with large variability between animals. In this experiment, 
differences between species remained the main source of variation, with low impact of other individual factors. To 
conclude, multiplicative and shedding capacity of Rev.1 was much higher in ibex compared to goats within 90 days. 
These results provide initial information on the potential use in natura of a commercial vaccine.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Brucella melitensis is a Gram-negative facultative intra-
cellular bacterium responsible for brucellosis in small 
ruminants, a widespread zoonosis in many sheep- and 
goat-raising countries worldwide [1–4].
Brucellosis eradication in small ruminants has been 
achieved in most of European Union (EU) countries 
through the implementation of long-term manage-
ment programs combining vaccination with serological 
testing and culling [5]. Until recently, terrestrial wild-
life had not been considered as a significant reservoir 
[6]. In France, no brucellosis cases have been reported 
in domestic ruminants since 2003 [7]. However, B. 
melitensis biovar 3 infection has been identified since 
2012 in Alpine ibexes (Capra ibex) in the Bargy Moun-
tains (Haute Savoie, France), after a local outbreak on a 
dairy cattle farm and two human cases declared in 2011 
[8–10]. The restriction of brucellosis to the Bargy area 
indicates a localized outbreak in wildlife. Until recently, 
Alpine ibexes had been considered to be epidemiological 
dead-ends for B. melitensis [6], but the high prevalence 
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observed in the Bargy area (38%) suggested the presence 
of an unexpected wildlife reservoir [11]. Focused culling 
of seropositive or ill ibexes and mass culling have been 
implemented since 2013, which reduced the population 
by half [12], raising the question of the social acceptabil-
ity of conducting mass culling in a protected species [11]. 
Moreover, this management strategy did not result in a 
significant reduction in seroprevalence [11, 12].
A scientific expert appraisal suggested that vaccination 
with the B. melitensis Rev.1 strain of ibex could be consid-
ered for better control of this wildlife reservoir [13, 14]. 
The Rev.1 vaccine, a stable live B. melitensis attenuated 
strain [15, 16], administered by the conjunctival route at 
standard doses is well known to induce good protection 
in sheep and goats against B. melitensis-related abortion 
[17, 18]. The main risks of vaccination are potential abor-
tion in female animals vaccinated during pregnancy and 
possible Rev.1 genital or milk excretion following vac-
cination [19–23]. Despite the phylogenetic closeness of 
ibex and domestic goats (Capra hircus) [24], experts have 
highlighted the importance of confirming vaccine safety 
in Alpine ibex before its application in natura [13, 25], 
taking into account the other potential negative impacts 
of a live Brucella vaccine reported in other wildlife spe-
cies [26–30], and potential interference with local moni-
toring and management programs [25]. It was therefore 
decided to design a study aimed at checking the innocu-
ousness of Rev.1 in non-pregnant sexually mature ibexes 
that are the most common captured/sampled age class 
(juveniles being, on the contrary, rarely captured) [12].
Because of ethical, regulatory, logistic and practical 
reasons, a virulent challenge in pregnant Alpine ibex 
requiring a biosafety level 3 (BSL-3) facility adapted to 
this wildlife species could not be considered [25].
Therefore, the objective of the present study was to 
assess the innocuousness of the Rev.1 conjunctival vac-
cine in non-pregnant sexually mature Alpine ibexes 
compared to domestic goats, and the subsequent risk of 
shedding and transmission to unvaccinated control ani-
mals. The hypothesis tested here was that sexually mature 
ibexes and goats have a comparable ability to control the 
vaccine.
Materials and methods
All experiments were conducted in accordance with 
EU guidelines and French regulations (Directive 
2010/63/EU, 2010; French Rural Code, 2018; French 
Decree No. 2013-118, 2013, [31]). All experimen-
tal procedures were evaluated and approved by the 
Ministry of Higher Education and Research (Noti-
fications: APAFIS#7643-2016112111336721 v4 and 
APAFlS#7913-2016112911444302 v3). Procedures con-
cerning goats were evaluated by the Ethics Committee 
of the Val de Loire (CEEA VdL, committee No. 19, 
APAFIS#7643) and took place at the INRA Experimen-
tal Infection Platform [32], whereas procedures for ibex 
were evaluated by the Cuvier Ethics Committee (CEEA 
Cuvier, Committee No. 68, APAFIS#7913) and took place 
at the Réserve Zoologique de la Haute Touche (RZHT, 
Obterre, France).
Selection of animals
A major difficulty in the present study was to pair goats 
and ibexes regarding their sexual maturity and health 
status, which is known to impact individual susceptibil-
ity to Brucella rather than age, since sexual maturity in 
ibex is much later (2 to 5 years) compared to the domes-
tic goat. Goats, on the contrary, are seldom raised for 
more than 4–5 years (roughly 4–6 months for bucks and 
6–18 months for goats [33]). Six male and six non-preg-
nant female ibexes were recruited from three zoologi-
cal parks (Parc des Angles, Domaine de Pescheray and 
RZHT, France). For the experiment, males and females 
were housed separately at the RZHT in two groups in a 
170 m2 facility specifically adapted to their welfare. Ani-
mal age ranged between 2.5 and 5  years (Table  1, [34, 
35]).
Twelve adult Alpine goats (six non-pregnant females 
and six males) were obtained from the INRA animal facil-
ity in Magneraud (France) and the company CAPGENES 
(CAPGENES, Agropole, Mignaloux-Beauvoir, France) 
(Table 1). During the trial, all animals were housed in the 
animal facilities, biosafety level 1 sheepfold animal facil-
ity at the INRA PFIE (INRA Centre de Recherche Val de 
Loire, Nouzilly, France).
Vaccination and sampling
The experiment (Figure  1) consisted in the conjunctival 
vaccination with Rev.1 vaccine  (Ocurev®, CZ Veteri-
naria, Spain; 1–2 × 109 CFU in 35 µL/doses) of 10 goats 
(divided into two groups: five females and five males) 
and 9 ibex (divided in two groups: four females and five 
males; the 5th female ibex was not vaccinated and kept 
as a contact animal, as diarrhea symptoms were observed 
on the day of vaccination). At the time of the vaccina-
tion, vaccinated animals and contacts were separated 
from each other in captivity to avoid iatrogenic interfer-
ence. The animals included in the experiment were nei-
ther pregnant nor lactating. For both species, one animal 
of each sex was used as an unvaccinated contact control, 
except for the female ibex (two contact controls). Vac-
cination was systematically performed according to the 
recommendations of the manufacturer for sheep and 
goats in the right eyelid. Within each batch, half of the 
animals (2 individuals vaccinated and 1 control) were 
euthanized at 45  days pv and the remaining animals at 
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90 days after anesthesia induction by ketamine/xylazine 
mixture  (Imalgene® 1000, Merial, France, 10 mg/kg and 
 Rompun®, Bayer Healthcare, France, 2  mg/kg adminis-
tered IM). Euthanasia took place on anesthetized animals 
by IV injection of  Euthasol®  (Euthasol®Vet 40%, LE VET, 
Netherlands, 1  mL/5  kg) for ibex and  Dolethal® (Veto-
quinol, France, 250 mL, 50 mg/kg) for goats. All animals 
were then necropsied.
Serological, bacterial, hematological and hormonal fol-
low-ups were performed at 0, 20, 45, 68, and 90 days pv 
with an additional blood sample at 7  days pv for goats. 
In parallel, ocular, nasal and vaginal or urethral swabs 
were collected for culture purposes (Table  2). Blood 
samples were collected by jugular venipuncture from all 
animals. They were prepared for bacteriological culture 
and assessment of serological response. All animals were 
blood-tested to check the seroconversion of vaccinated 
animals and potential exposure to the vaccine strain 
of unvaccinated contact animals. Vaginal and urethral 
swabs were performed in females and males, respectively. 
Ocular and nasal swabs were collected from the inocu-
lated head-side in vaccinated animals and from both 
sides in contact animals (Table 2). Swabs were prepared 
for bacteriological culture.
As environmental samples, five manure samples per 
pen were also collected on day 68 pv in both locations 
(female and male pens).
Necropsy, tissue collection and preparation
Necropsies, in a BSL-3 necropsy room, were per-
formed at the PFIE. Urine was collected during nec-
ropsy (Table  2). Tissues removed aseptically included 
parotid, retropharyngeal, sub-maxillary (head lymph 
nodes), uterus (female) or testes (male), supra-mammary 
(female) or inguinal (male) and iliac lymph nodes (pelvic 
organs), pre-scapular lymph nodes, and spleen (Figures 1 
and 2). Tissue samples were prepared according to OIE 
requirements [17] (Table 1). Other specimens were kept 
frozen at −80 °C.
Control of the Rev.1 vaccine batch
Concentrations of bacteria in the  Ocurev® vaccine batch 
(number 164164) was previously controlled by the French 
National Reference Laboratory (NRL) for brucellosis by 
Table 1 Individual characteristics of the 12 Capra ibex and 12 Capra hircus included in the study and applied vaccine 
treatment 
a Death of 3 goats occurred during the experiment, only goat 20 055 was included in the analysis.
*Corresponding to the number of death of 3 goats.
Species Group Housing Birth date Identifier Sex Age (years) Treatment Day of necropsy
Capra ibex A Haute Touche 01/05/2013 1890 M 3–5 Vaccinated D45
01/05/2013 2000 M 3–5 Vaccinated D90
01/05/2012 1895 M 3–5 Control D90
01/05/2012 1839 M 3–5 Vaccinated D45
01/05/2014 1828 M < 3 Vaccinated D45
01/05/2014 3094 M < 3 Vaccinated D90
Capra ibex B Haute Touche 01/05/2012 1926 F 3–5 Control D90
01/05/2012 1920 F < 3 Vaccinated D45
01/05/2012 1933 F 3–5 Vaccinated D45
01/05/2013 2393 F < 3 Vaccinated D90
01/05/2014 2349 F < 3 Control D45
31/05/2002 7462 F > 5 Vaccinated D90
Capra hircus C PFIE 31/08/2015 62 107 M < 3 Vaccinated D90
04/02/2016 16 142 M < 3 Vaccinated D45
16/02/2016 06 145 M < 3 Vaccinated D45
14/02/2016 61 003 M < 3 Vaccinated D45
15/02/2016 61 275 M < 3 Vaccinated D90
03/12/2012 13 101 M 3–5 Control D90
Capra hircus D PFIE 30/08/2010 10 139* F > 5 Vaccinated 19/02/2017a
26/08/2011 20 055* F > 5 Vaccinated 27/03/2017a
07/09/2012 30 313* F 3–5 Vaccinated 12/02/2017a
31/08/2013 40 176 F 3–5 Vaccinated D90
02/09/2014 50 105 F < 3 Vaccinated D90
27/08/2011 20 072 F > 5 Control D90
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standard plate counts in accordance with OIE require-
ments [17] and approved before use. Moreover, one 
 Ocurev® vaccine vial used for goat vaccination was con-
trolled for purity and colonial morphology after conjunc-
tival instillation, according to the same procedure.
Zootechnical monitoring and behavior
Animal welfare was monitored twice per day by assess-
ing and scoring the following four general categories: 
(a) behavior, (b) thermal comfort, (c) feeding, and (d) 
body condition. An endpoint to the experimental pro-
cedure was planned according to scoring in case major 
clinical signs of pain and distress would have been 
observed: hyperthermia (> 41  °C), prostration, ano-
rexia, diarrhea and/or vomiting, significant weight loss, 
tissue necrosis, biting.
Blood cell analyses
Blood cells were counted with a MS9-5 Hematol-
ogy  Counter® (digital automatic hematology analyzer, 
Melet Schloesing Laboratories, France) and analyzed to 
characterize total white blood cells, red blood cells, and 
platelets [36, 37].
Acclimazaon of 
Capra species
N = 12 (6-6), 2-5 years
D0 D45 D90
Ocular vaccinaon by OCUREV® (B)
4 groups: 
Group A (n = 4 vaccinated + n = 2 contact controls 
female Capra ibex) 
Group B (n = 5 vaccinated + n = 1 contact control 
male Capra ibex)
Group C (n = 5 vaccinated + n = 1 contact control 
female Capra hircus)
Group D (n = 5 vaccinated + n = 1 contact control 
male Capra hircus)
Necropsies of 2 vaccinated + 1 contact control 
female and 3 male vaccinated Capra ibex 
+
Necropsies of 3 female vaccinated and 3 male 
vaccinated Capra hircus
Collect of different ssues and samples
Post-vaccinaon following during 3 months
Blood tests for serology, haematology, hormonology and bacteraemia 
Days: D0, D7, D20, D45, D65 et D90
D68D20
Nasal, ocular, vaginal 
or urethral swabs
Nasal, ocular, vaginal 
or urethral swabs
Nasal, ocular, vaginal 
or urethral swabs
Nasal, ocular, vaginal 
or urethral swabs
D7
(only for Capra hircus) 
Necropsies of 2 vaccinated + 1 contact control 
female and 2 vaccinated + 1 contact control 
Capra ibex 
+
Necropsies of 2 vaccinated + 1 contact control 
female and 2 vaccinated + 1 contact control 
Capra hircus
Collect of different ssues and samples
A
B
Figure 1 Experimental design of vaccination with Brucella melitensis Rev.1 strain of Capra ibex and C. hircus. A Experimental design of 
ocular vaccination in Capra ibex and hircus and B inoculation of  OCUREV® vaccine by ocular pathway at 1 × 109 CFU/drop.
Table 2 Swab and blood collection on days 0, 20, 45, 68 and 90, and urine and tissue collection at necropsy on day 45 or 
90 after conjunctival vaccination on day 0 with the B. melitensis Rev.1 strain 
Vaccinated animals Contact animals
Collection during post‑vaccination kinetics Ocular and nasal swabs Ocular and nasal swabs
From the inoculated head‑side (1 swab) From both head‑sides (2 swabs)
Vaginal and urethral swabs/blood Vaginal and urethral swabs/blood
Collection at necropsy Head lymph nodes Head lymph nodes
From the inoculated head‑side From both head‑sides and pooled
Iliac, supramammary and inguinal lymph nodes from both sides 
and pooled
Iliac, supramammary and ingui‑
nallymph nodes from both 
sides and pooled
Spleen Spleen
Urine aspirated from bladder Urine aspirated from bladder
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Bacteriological cultures
Specimen preparation
Tissue samples and swabs were transferred to the bac-
teriology laboratory within 2  h following necropsies 
and then directly handled as following: tissue samples 
were mixed in a tissue grinder with sterile PBS (two-
fold dilution), before being inoculated onto solid media. 
Each swab was rehydrated in PBS, before being streaked 
directly onto two plates, then incubated at 37 °C. Whole 
blood was centrifuged (600 g, 15  min). The concentrate 
was diluted 1:6 in a trypticase soy broth with 5% vol./vol. 
equine serum. Broths were incubated in a 5%  CO2 added-
atmosphere at 37  °C. Subcultures were initiated every 
3 days using Farrell’s solid medium (0.2 mL of broth/dish) 
until 35 days.
Manure samples were cut and diluted 1:2 in sterile PBS, 
then incubated overnight at 37  °C, before DNA extrac-
tion for molecular detection [38] and culture for bacterial 
detection. For this particular matrix, the lower limit of 
detection was determined from manure samples spiked 
with calibrated broth suspensions of B. melitensis biovar 
3 (Ether-ATCC 23458).
Culture protocol
Culture of blood, swabs and tissue samples was per-
formed on selective modified Farrell’s medium formu-
lated from non-selective solid agar medium and Brucella 
selective supplement (Blood Agar Base No. 2, OXOID 
CM0271, supplemented with modified Brucella Selec-
tive Supplement, OXOID SR0209 and 5% vol./vol. equine 
serum). Each specimen (0.2  mL of prepared specimen) 
was incubated on 4 plates at 37  °C. The plates were 
checked for up to 10  days for the presence of bacterial 
growth; strains were then isolated and identified using a 
combination of growth characteristics and bacteriologi-
cal methods [17, 39]. Molecular identification included 
real-time PCR and Bruce-ladder methods [38, 40].
Serological analyses
Blood samples were processed according to stand-
ard procedures in a BSL-3 laboratory. Whole blood 
was centrifuged (600 g, 15  min). Sera were examined 
for the presence of smooth Brucella antibodies using 
RBT  (Pourquier® Rose Bengal Ag, IDEXX) and CFT 
 (Pourquier® CFT Brucellosis Ag, IDEXX) antigens. The 
lowest detection limits for CFT assays were determined 
and expressed as CFT titers (ICFTU/mL). Both antigens 
were standardized against the OIE International Stand-
ard Serum (OIEISS, APHA, Weybridge, UK) and the test 
performed according to OIE and EU requirements (any 
visible agglutination reaction was considered positive 
for RBT; positivity threshold of 20 ICFTU/mL for CFT). 
RBT results were expressed as a score ranging from 0 (no 
visible agglutination) to 4 (complete agglutination).
Statistical analyses
Serological results from vaccinated animals were ana-
lyzed according to three criteria: (i) the score of agglu-
tination with the RBT, from 0 (no agglutination) to 4 
(complete agglutination); (ii) the CFT titer (ICFTU/mL) 
1) Nasal and 
eye swabs (*) 
2) Lymph 
nodes of the 
head (*) 
3) Blood  
5) Genital swab, bladder 
swab or urine (*) 
4) Lymph nodes of the 
pelvic area (*) 
Expected Rev.1 spread with 
increased shedding risk from 
the inoculaon point (eye) 
to the pelvic organs (urine, 
genital tracts) 
Figure 2 Organ/swab classification according to localization and shedding potential in both goats and Alpine ibexes. (1) lymph nodes 
from the head (local multiplication), (2) nasal and ocular swabs (low shedding potential), (3) blood, (4) lymph nodes from the pelvic area (urogenital 
multiplication and potential shedding), (5) genital or bladder swabs (high shedding potential).
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corresponding to the end-point of the reaction; and (iii) 
the individual serological status combining RBT and CFT 
results: seropositive (positive results with RBT and CFT) 
or seronegative (negative results with RBT or CFT). To 
account for the cluster effect of each individual, a mixed 
model was used, the identity of each individual being 
used as a random effect [41]. The fixed effects accounted 
for in serology were the species (ibex, goat), the time of 
sampling (20, 45, 68, 90 days pv), and the presence of bac-
teremia on day 20 pv (yes/no). Sex of animals was tested 
as fixed effect but was not kept in the final model as it 
didn’t improve significantly the model fitness.
We analyzed bacteriological results from vaccinated 
animals according to different “innocuousness criteria” 
accounting for Rev.1 dissemination and the individual 
ability to contain the live-vaccine: (i) an indicator of 
Rev.1 strain dissemination among vaccinated individuals, 
by considering the proportion of organs positive to cul-
ture, (ii) an indicator of vaccine strain shedding potential 
among vaccinated individuals, by considering the pro-
portion of culture-positive organs from the pelvic area; 
and (iii) the bacterial burden among infected organs or 
swabs. We analyzed hematological results from vacci-
nated or non-vaccinated animals according to different 
“innocuousness criteria” after Rev.1 vaccination in func-
tion of time, sex and genders, using GraphPad Prism soft-
ware version 5.0 (non-parametric tests: Kruskall-Wallis, 
Mann–Whitney tests,  GraphPad®, San Diego, Ca, USA).
The two first variables were defined as the proportion 
of culture-positive organs/swabs/blood sampled on each 
vaccinated individual and at each sampling time, either 
at the whole animal level (i) or only the pelvic organs. 
(ii) Animals excluded from the study before the 20th 
day post-vaccination (i.e., two dead female goats) were 
not included in these analyses. To account for the clus-
ter effect of each individual, a logistic mixed model was 
used, the identity of each individual being used as a ran-
dom effect [42]. The fixed effects accounted for were spe-
cies, gender, time of sampling (20, 45, 68, 90 days pv), and 
type of sampling event (in vivo sampling, necropsy). The 
third variable was defined as the total number of colonies 
counted among the culture-positive organs or swabs. (iii) 
This variable was log-transformed and modelled accord-
ing to a Gaussian mixed model (random effect). This 
analysis focused on necropsy samples only (i.e. days 45 or 
90 pv). The number of plates was variable among organs 
(from 1 to 4), mainly due to varying organ/swab nature or 
size; the number of plates was thus introduced as a model 
offset. The fixed effects accounted for were species, gen-
der, time of necropsy, and type of organ (Figure 2).
Model selection was based on the Akaike Informa-
tion Criterion (AIC, [43]). Statistical analyses were per-
formed using R software version 3.4.2 (the R foundation 
for statistical computing, 2017), and the lme4 [44] and 
MuMIn packages [45].
Results
Vaccine control testing
The control of the Rev.1 vaccine strain performed post-
vaccination showed that the strain was pure and smooth. 
Actual concentration measured by viable counts on TSA-
YE medium, 1.6 × 109 CFU/dose, was consistent with 
that of the manufacturer (1 to 2 × 109 CFU/dose).
Zootechnical monitoring and behavior
Ibexes
No clinical signs were observed during the acclimatiza-
tion phase. The experimental protocol therefore focused 
on nine vaccinated animals (five males and four females) 
and three contact controls (one male and two females). 
During the experiment, clinical follow-up of the animals 
showed episodic diarrhea (a gastro-intestinal food sup-
plement of the  Phoscargil® type (San’Elevage, Changé, 
France) was administered to all the animals); one diar-
rheic female ibex was not vaccinated for this reason and 
included as a control. No major hyperthermia, polypnea, 
tachycardia, prostration, anorexia, weight loss or com-
plaints were observed in the animals. Furthermore, in 
both live animals and at autopsy, no gross lesions sugges-
tive of brucellosis infection (such as described by Freycon 
et al. and Lambert et al. [46, 47]) were observed in vac-
cinated or contact animals, particularly in the genitalia, 
udder or joints. No loss of appetite or body condition, 
trauma, or aggressive behavior were observed, despite 
close contact between individuals of the same batch over 
an extended period of 3 months.
Goats
No clinical signs were observed during the acclimatiza-
tion phase nor during vaccination of the goats, except for 
a buck that had strong nasal discharge on day 5 pv, which 
then resolved without treatment. Nevertheless, two vac-
cinated female goats died without clinical signs on day 6 
and day 13 pv, respectively probably in connection with 
other concomitant diseases and poor body condition of 
the latter. A third vaccinated goat showed post-vaccina-
tion mastitis on day 42 and was euthanized on day 43 for 
animal welfare reasons (exceeded endpoints).
Total and differential white blood cell counts in the blood
In addition to significant individual variability, blood 
counts varied with treatment (vaccination/contact), post-
vaccination stage, species, and sex of animals. There was 
no sex effect on hematological parameters, but a signifi-
cant effect of species was observed especially for total 
number of white cells (P < 0.05). Following vaccination, a 
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significant decrease in the concentration of white blood 
cells was observed in both vaccine species on D45 and 
D90 (P < 0.05; Figures 3A and B). No significant decrease 
during follow-up kinetics was observed in unvacci-
nated animals. However, the difference between species 
remained significant throughout the experimental period 
(P < 0.05).
A higher initial lymphocyte to neutrophil (L/N) ratio 
was observed in ibex females in comparison with female 
goats (Figure  3C), but this was not significant. In vac-
cinated ibexes, a gradual increase of the L/N ratio was 
observed between D0 and D68 and was only signifi-
cant on D68 compared to D0 (in favor of lymphocytes, 
P = 0.04), corresponding to the multiplication of anti-
body-producing cells (Figures 3C and  D). In vaccinated 
goats, a more rapid gradual increase of the L/N ratio was 
observed between D0 and D20 and was only significant 
on D20 versus D0 (P = 0.02). This response occurred later 
and with a higher intensity in ibexes compared to goats.
Serological response
Changes in serological response after vaccination in both 
RBT and CFT are shown in Tables  3 and 4. Significant 
effects of day of sampling were observed for both CFT 
titers and RBT scores, with maximum values reached 20 
and 45 days pv for RBT and CFT, respectively (3.6 ± 0.2 
and 973 ± 187 ICFTU/mL). As expected, all animals 
showed seroconversion within 45  days pv [48] (Fig-
ures  4 and 5). However, the serological response (RBT 
score and CFT titers) was more intense and persistent in 
ibexes than in goats, with differences averaging 920 ± 257 
ICFTU/mL and 1.5 ± 0.19 for RBT and CFT, respec-
tively (P < 0.0001). The presence of bacteremia increased 
the antibody response observed with RBT. All ibexes 
remained seropositive throughout the experiment (with 
RBT- and CFT-positive results), whereas only one goat 
remained seropositive on day 90 pv as described in Pon-
sart et al. [48]).
Kinetics and distribution of the B. melitensis Rev.1 vaccine
In total, 375 bacteriological samples were analyzed 
from the 22 animals that survived more than 20 days pv 
(i.e., 10 goats and 12 ibexes, 17 vaccinated and 5 unvac-
cinated). Of these 375 samples, 94 were found to be 
culture-positive [48]. All vaccinated animals exhibited 
at least one positive culture, all being positive at the 
time of necropsy in the head region, irrespective of the 
species or time post-vaccination (local initial multipli-
cation). Furthermore, the contact ibex male was found 
to be infected by the Rev.1 strain (6 from 11 examined 
Figure 3 Evolution of total leucocyte and lymphocyte/neutrophil ratios (L/N) in Capra ibex and C. hircus. Blood was collected on days 0, 
7 (only for C. hircus), 20, 45, 68 and 90 after conjunctival vaccination on day 0 with Brucella melitensis Rev.1 strain. A, C Capra ibex and B, D C. hircus. 
Vaccinated males and females (black triangles, continuous lines and black circles‑dotted lines, respectively), compared with control animals (A–D), 
males and females (empty triangles, continuous lines and empty circles‑dotted lines respectively). **P < 0.05; *P = 0.02; #P = 0.04.
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organs being culture-positive), while the four other 
contacts (one female and one male goat, two female 
ibexes) were found negative at the time of necropsy.
The proportion of culture-positive organs was stud-
ied among 50 sampling*individual events collected 
in  vivo or at the time of necropsy among 17 vacci-
nated animals. Significant effects of time pv, of mode 
of sampling, and of species were observed, but there 
was no significant effect of animal gender (this was not 
retained in the best model according to the AIC model 
values). The probability of observing positive results 
was logically much lower during in vivo sampling com-
pared to necropsy time  (ORin vivo/necropsy = 0.037, 95% CI 
[0.005; 0.289]). As expected, based on a previous study, 
this probability was also lower at day 90 pv compared to 
day 45 pv  (OR90 versus 45 = 0.091, 95% CI [0.010; 0.860]). 
The proportion of culture-positive organs was higher 
in the ibexes compared to the domestic goats  (ORibex/
goat = 4.184, 95% CI [2.311; 7.574]). When focusing the 
analysis on the organs from the pelvic region, the spe-
cies effect was again the most important factor  (ORibex/
goat = 7.222, 95% CI [2.192; 23.799]), and the mode of 
sampling was still significant  (ORin vivo/necropsy = 0.154, 
95% CI [0.032; 0.733]), while the period had no signifi-
cant effect.
In ibexes, average Rev.1 burdens in infected organs 
ranged from 1 to 300 on day 45 pv and from 1 to 100 at 
day 90  pv. In goats, average Rev.1 burdens ranged from 
1 to 30 on day 45 pv and from 1 to 10 on day 90 pv. The 
bacterial burden (log-transformed) was studied for 
Table 3 Simultaneous tests for general linear hypotheses explaining RBT score and CFT titers (Lmer4 package, animal 
considered as random effect) 
Fixed effects Level CFT titers (ICFTU/mL) RBT score
Estimate ± standard 
error
z value Probability > |z| Estimate ± standard 
error
z value Probability > |z|
Intercept 516 ± 313 1.65 0.09 1.5 ± 0.3 6.0 < 0.0001
Day of sampling pv 0 –
20 449 ± 187 2.4 0.02 3.6 ± 0.2 19.4 < 0.0001
45 973 ± 187 5.2 < 0.0001 3.6 ± 0.2 19.4 < 0.0001
68 863.1 ± 239 3.6 0.0003 3.4 ± 0.2 14.7 < 0.0001
90 460 ± 239 1.9 0.05 3.0 ± 0.2 13.1 < 0.0001
Species Goat –
Ibex 920 ± 257 3.6 0.0003 1.5 ± 0.19 7.7 < 0.0001
Bacteremia 20 days pv No –
Yes 128 ± 273 0.5 > 0.05 1.2 ± 0.2 5.9 < 0.0001
Table 4 Mean CFT titers (mean titer ± SEM; CFT) and number of goats and ibexes positive in Rose Bengal tests (RBT) from 
20 to 90 days after conjunctival vaccination with Brucella melitensis Rev.1 strain (all samples were negative at D0 in both 
tests) 
a Number of animals per group.
b One male control ibex presented a seroconversion on day 68.
*Corresponding to the unvaccinated Ibex second control seroconversion.
Group D20 D45 D68 D90
CF RBT CF RBT CF RBT CF RBT
Necropsied on D45
 Vaccinated ibex (5)a 810 ± 397 5 1984 ± 1048 55
 Control ibex (1) 0 0 0 0
 Vaccinated goats (4) 322 ± 432 4 82 ± 61 4
 Control goats (0) – – – –
Necropsied on D90
 Vaccinated ibex (4) 527 ± 440 4 1493 ± 708 4 1573 ± 646 4 773 ± 305 4
 Control ibex (2) 0 0 0 0 0 vs. 160* 1b 0 vs. 160* 1b
 Vaccinated goats (4) 45 ± 39 4 78 ± 63 4 25 ± 15 4 20 ± 35 3
 Control goats (2) 0 0 0 0 0 0 0 0
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Figure 4 Evolution of CFT titers (ICFTU/mL) and RBT scores in Capra hircus. A Vaccinated goats, necropsied 45 days post‑vaccination, and 
B vaccinated and control goats both necropsied 90 days post‑vaccination. Titers and scores were obtained on days 0, 20, 45, 68 and 90 after 
conjunctival vaccination on day 0 with B. melitensis Rev.1 strain, in both males (M) and females (F) (squares continuous lines for CFT titers and 
respectively diamonds in dotted lines for RBT score).
Figure 5 Evolution of CFT titers (ICFTU/mL) and RBT scores in Capra ibex. A Vaccinated ibexes and control ibex (identified 2349) necropsied 
45 days post‑vaccination, and B vaccinated and control ibexes (identified 1926 and 1895) necropsied 90 days post‑vaccination. Titers and scores 
were obtained on days 0, 20, 45, 68 and 90 after conjunctival vaccination on day 0 with Brucella melitensis Rev.1 strain, in both males (M) and females 
(F) (squares continuous lines for CFT titers and respectively diamonds in dotted lines for RBT score).
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culture-positive organs examined at necropsy among 17 
vaccinated individuals (either necropsied 45 or 90  days 
pv). Significant effects of time of necropsy (45 or 90 pv), 
of organ type, and species were observed, but there was 
no significant influence of animal gender. The bacterial 
burden was significantly lower in the head swabs (ocular 
or nasal) compared to any other organs, including geni-
tal and bladder swabs (PEx_head/Ex_genital = −4.876, 95% CI 
[−8.229; −1.523]). The bacterial burden was found to be 
about 10 times lower 90 days pv compared to 45 days pv 
(P90 vs 45 = −2.1671, 95% CI [−3.145; −1.188]). The bac-
terial burden of the culture-positive organs was also at 
least 10 times higher in ibexes compared to goats (Pibex/
goat = + 2.410 (see Footnote 1), 95% CI [+ 1.409; 3.411]). 
The interaction between the period and the species was 
not significant.
Bacterial analyses in animal litter
None of the manure samples collected 68  days pv 
revealed the presence of Brucella (DNA detection and 
bacteria isolation). The efficiency and the sensitiv-
ity of both methods were comprised between  102 and 
 104 CFU/g using the B. melitensis reference strain (data 
not shown).
Discussion
As expected during a successful Rev.1 vaccination, all 
vaccinated animals seroconverted and exhibited loco-
regional Rev.1 strain multiplication. None of these vac-
cinated animals developed detectable lesions nor clinical 
signs attributable to the Rev.1 vaccine [5, 19, 49]. How-
ever, contrary to the experts’ expectations, our results 
revealed a highly contrasting vaccine outcome between 
the two species, which invalidated the hypothesis of com-
parable innocuousness of the Rev.1 vaccine between the 
Alpine ibex and the domestic goat.
Rev.1 distribution and burden in Alpine ibex and domestic 
goat
The proportion of Rev.1-infected samples and the bac-
terial burdens observed in culture-positive organs were 
significantly higher in ibexes compared to goats. In 
goats, vaccination is likely to give rise to a bacteremia 
and a generalized infection [50]. Elberg and Meyer [51] 
showed that tissues of subcutaneous vaccinated goats 
have practically cleared themselves of Rev.1 vaccine by 
14 weeks post-vaccination, a duration which is shortened 
through vaccination by the conjunctival route [51–53]. 
In this experiment, differences between species were the 
dominant factor, with negligible effects of individual fac-
tors such as gender. The proportion of infected organs, 
both at the whole individual level or focusing on the pel-
vic organs, decreased over time but remained moderate 
at 90 days pv in both species, with considerable individ-
ual variability. These results suggest a higher risk of Rev.1 
shedding between day 20 and day 68 in ibex, but given the 
positive culture observed on day 90 pv, it is not possible 
to rule out potential persistence and shedding in the long 
term in vaccinated ibexes (or goats [19]). Sparse data have 
been published on vaccination of adult non-pregnant 
female deer. However, prolonged serological responses 
[54], as well as milk excretion, [22] have been reported, 
supporting the hypothesis of possible systemic infection. 
Two vaccinated male ibexes presented urogenital excre-
tion 20, 45 or 68 days pv, which was not observed in the 
other vaccinated batches. As a logical consequence, the 
control male ibex sharing the same box seroconverted 
between 45 and 68 pv and exhibited a similar Rev.1 bur-
den to its vaccinated fellows when necropsied 90  days 
pv. It has been previously shown that the persistence of 
Rev.1 in vaccinated goats on the conjunctiva, and in nasal 
secretion as well in the saliva is weakly detectable up to 
15  days post vaccination [19]. This local scattering had 
no effect on sentinel goats (swabs and serology remained 
negative) indicating that there was no contamination 
by the vaccine strain (I. Jacques, personal communica-
tion). In Portugal, a study reported that sentinel animals 
remained negative in serology when placed with goats 
vaccinated by Rev.1 [55]. Given that no live bacteria were 
found in animal litter, and the low resistance of the Rev.1 
vaccine to ultraviolet exposure, impacting its DNA repair 
mechanisms [56], one may presume that the sentinel 
male ibex infection was favored by the close contact with 
vaccinated males sharing the same box. The A1 housing 
used here is obviously not a comparable situation to the 
natural environment, where Rev.1 survival is certainly 
impaired by adverse environmental conditions (tempera-
ture, ultraviolet light, etc.). Nevertheless, the distribution 
of Rev.1 suggests a far lower ability of Alpine ibex to con-
trol Rev.1 multiplication, and a higher risk of Rev.1 shed-
ding and further transmission to control individuals than 
in domestic species. Given this discrepancy, it is also very 
difficult to assess vaccine efficacy in Alpine ibex based 
on experiments done in domestic species; we may even 
hypothesize logical higher susceptibility of Alpine ibex 
to side effects such as abortions. Differences in vaccine 
effects in wild and domestic species have been observed, 
particularly in the American bison (Bison bison) and elk 
(Cervus canadensis) regarding B. abortus [57]. These 
American-native species were found to be more suscepti-
ble to abortion caused by attenuated live-vaccine than the 
domestic cow (Bos taurus) imported from Europe [26, 27, 1 The data have been log-transformed; please consider the parameter on the 
log-scale.
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30]. In the case of the Alpine ibex, we may hypothesize 
that its remote and sparse historical distribution [58] 
resulted in limited co-evolution with livestock pathogens 
including Brucella. In addition, intensively hunted Alpine 
ibex almost became extinct during the nineteenth cen-
tury, and its recent restauration has been based on small 
animal numbers [59]. This historical background may 
have resulted in genetic bottleneck events and a consecu-
tive decrease in immune capacity [60]. Further studies 
are clearly required to investigate these hypotheses and 
the mechanisms for species resistance regarding Brucella 
infection.
Immune response
An important result of this experiment concerns the 
intensity of the highly contrasted immune reaction 
between the two species. This differentiated dynamic 
between goats and ibexes may reflect different immune 
response mechanisms between the two species. The Bru-
cellae are intracellular bacteria that elicit both humoral 
and cell-mediated immune response. The S-LPS Bru-
cella major antigen elicits a T-cell dependent immune 
response with IgG1 dominating. The switch between IgM 
and IgG occurs in less than 7 days in adults implying that 
the detection of the early humoral response mainly relies 
on IgG [61]. Goats vaccinated with the standard dose 
1 × 109 CFU by the conjunctival route showed a weak and 
short humoral response, negative after 4  months [49]. 
However, the antibody response is mostly more signifi-
cant in adults than in immature animals [5, 61]. In this 
study, humoral response was more intense and prolonged 
in ibexes compared to goats on the basis of RBT and 
CFT, with persistent positive results in all ibexes until the 
end of the experiment. White cell counts exhibited a sim-
ilar trend: an increase in the production of lymphocytes 
at the expense of neutrophils later, and that was more 
intense and lasting in ibexes compared to goats. Recently, 
a stronger pro-inflammatory response has been observed 
in B. melitensis 16 M-infected pregnant goats compared 
to Rev.1 at day 28 post-infection together with a greater 
rise in mononuclear numbers, thus highlighting impacts 
of strain attenuation on cell-mediated immune response 
in goats [50]. The development of the immune response 
to Brucella infection is not well documented in ibex, even 
though the high CFT titers observed in the Bargy area’s 
ibexes suggest a stronger and longer serological response 
in ibex naturally infected by B. melitensis biovar 3 com-
pared to the domestic species infected by the same strain 
[47]. This study represents, to our knowledge, the first 
observation of longitudinal monitoring of seroconver-
sion on this species following contact with a B. melitensis 
strain and over a duration of 3 months.
To conclude, the antibody dynamics support the evi-
dence of different immune responses to the Rev.1 vac-
cine between the Alpine ibex and the domestic goat, with 
ibexes investing far more in humoral response than goats. 
In spite of this seemingly stronger immune response, the 
ibex seems much less effective than the goat in contain-
ing the multiplication of this intracellular bacterial strain. 
Comparable strong antibody responses have previously 
been reported in elk vaccinated with RB51, together with 
prolonged bacteremia and slower detectable prolifera-
tive responses in PBMC when compared to responses in 
cattle or bison [62, 63]. Protection against Brucella, as an 
intracellular pathogen, is believed to be mainly associated 
with Th1-type cell response, and the subsequent activa-
tion of cytotoxic T cells, NK cells, and macrophages [64]. 
In comparison, cytokines associated with a Th2-type 
response can stimulate antibody responses but can also 
have negative regulatory effects on Th1-type responses 
[65]. In the elk species, despite robust antibody responses 
to Brucella, the Th1–Th2 paradigm was the main hypoth-
esis to explain the lack of cellular immune responses and 
associated reductions in vaccine protection [29, 63]. Our 
results lead to similar hypotheses in the ibex species. This 
might correspond to a “naïve” immune response in wild 
species, possibly because they did not co-evolve with 
Brucella, unlike domestic ruminant species, and/or to 
an intrinsic lower immune capacity regarding this path-
ogen. Further studies are required to better understand 
immune responses in wild and domestic ruminant spe-
cies regarding Brucella, and their involvement in disease 
development and shedding outcomes.
In conclusion, tissue localization, shedding of bacteria, 
and humoral immune responses differ between Alpine 
ibexes and goats after conjunctival vaccination with B. 
melitensis Rev.1 strain. Ibex expressed more intense and 
prolonged humoral immune response than the domes-
tic goat, whereas the distribution and organ burdens of 
the vaccine strain were at least 10 times higher in ibex, 
particularly in the urogenital organs. Two out of five vac-
cinated male ibexes shed Rev.1 during the experiment, 
which resulted in the transmission of Rev.1 to the con-
trol male and its seroconversion. Alpine ibexes showed a 
lower capacity to contain the Rev.1 live-vaccine than the 
domestic species, and thus represent a higher risk of vac-
cine strain shedding. The practical constraints associated 
with the use of the vaccine in natura i.e., vaccination only 
possible in captured ibexes in the spring, including preg-
nant females, are likely to worsen the excretion of vaccine 
strain spread, with potentially disruptive effects on the 
monitoring and management of this wild reservoir. This 
study focused on the vaccine’s innocuousness and not on 
its efficacy or field deployment; therefore, our conclusion 
is not definitive concerning vaccine use in natura, but 
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could contribute to ongoing risk assessment and research 
addressing the efficacy of disease management strategies.
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